Skip to main content

Moderna’s stock soars then dips after questions arise around the limited data shared about its COVID-19 vaccine

Investors in Moderna Inc., the preclinical biotechnology company developing one of the front-running COVID-19 vaccines in the U.S., may face a volatile ride through the clinical trial process.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.